查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999479

發炎性腸道疾病治療市場：2026-2032年全球市場預測（依治療方法、給藥途徑、劑型、應用、最終使用者、分銷管道和病患類型分類）

Inflammatory Bowel Disease Treatment Market by Treatment Type, Route Of Administration, Formulation Type, Application, End-User, Distribution Channel, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，發炎性腸道疾病治療市場價值將達到 209.5 億美元，到 2026 年將成長至 219.5 億美元，到 2032 年將達到 294.7 億美元，複合年成長率為 4.99%。

主要市場統計數據
基準年 2025 209.5億美元
預計年份：2026年 219.5億美元
預測年份 2032 294.7億美元
複合年成長率 (%) 4.99%

對影響發炎性腸道疾病治療生態系統的新興趨勢和關鍵促進因素進行全面概述。

發炎性腸道疾病 (IBD) 涵蓋了頻譜複雜的慢性胃腸道疾病，其特徵是反覆發炎、患者患病率高，且迫切需要更有效的治療方法。近年來，先進生物製藥、精準醫療方法以及不斷成長的真實世界數據的融合，徹底改變了我們對該疾病病理生理學和治療模式的理解。隨著分子分型和創新終點指標在臨床試驗中越來越廣泛的應用，從藥物研發到醫療保健系統等相關人員都在重新思考其策略，以最大限度地掌握新的機會。

發炎性腸道疾病領域正在發生變革性變化，重新定義研究、治療方法和患者預後。

發炎性腸道疾病領域正經歷著一場根本性的變革，這主要得益於標靶免疫學和再生醫學的突破性進展。過去，小分子藥物和皮質類固醇佔據主導地位，但如今市場正轉向精準靶向的生物製劑，例如整合素受體拮抗劑和白細胞介素抑制劑，這些藥物具有更高的安全性和有效性。同時，基因治療載體、微生物組調節劑和幹細胞移植等先進治療方法也正進入後期研發階段，可望透過恢復黏膜完整性和免疫穩態，實現持續緩解。

預計 2025 年美國關稅對 IBD 治療領域療法創新和市場進入的累積影響。

美國計劃於2025年調整關稅政策，可能會對發炎性腸道疾病（IBD）治療藥物的供應鏈和成本結構產生廣泛影響。關鍵原料和活性藥物成分進口關稅的提高，可能迫使製造商調整籌資策略，承擔額外成本，並影響價格談判和報銷協商。因此，決策者需要密切關注政策動態，並探索替代原料來源和本地生產夥伴關係，以降低成本上升的風險。

細分分析的詳細信息，以明確治療方法、給藥途徑、劑型、用途、最終用戶和患者人口統計特徵。

發炎性腸道疾病 (IBD) 治療市場已從多個維度進行分析，旨在識別關鍵機會和未滿足的需求。根據治療類型，研究工作涵蓋了從氨基水楊酸鹽、皮質類固醇和免疫抑制劑等基礎小分子藥物到腫瘤壞死因子抑制劑、白細胞介素抑制劑和整合素受體拮抗劑等前沿生物製藥。此外，基因療法（旨在重置免疫調節）、微生物組調變器（旨在恢復腸道菌群平衡）以及幹細胞療法（專注於再生受損腸道組織）等先進治療方法進一步豐富了治療方案。對於難治性病例，手術介入仍然至關重要，包括切除術、腸切除術和狹窄成形術等，這些手術均需根據複雜的解剖結構進行調整。

區域洞察：揭示美洲、歐洲、中東和非洲以及亞太地區發炎性腸道疾病治療領域的獨特成長要素和病患可及性趨勢

區域趨勢正以不同的方式影響發炎性腸道疾病（IBD）的治療模式。在美洲，完善的醫療基礎設施和成熟的報銷機制促進了新治療方法的快速普及。患者權益組織和臨床網路正在提高公眾對疾病的認知，並支持早期診斷和長期治療方案的依從性。然而，新的挑戰包括如何審查高價生物製藥的支付方，以及如何透過全面的患者登記資料來證明其在實際臨床應用中的價值。

公司簡介和競爭定位，重點關注炎症性腸道疾病治療領域的創新路徑和市場領導地位。

領先的製藥和生物技術公司正採取多元化策略，以鞏固其在發炎性腸道疾病（IBD）領域的地位。老牌主要企業正透過新一代抗體結構和生物相似藥開發項目，強化其生物製劑產品系列。同時，新興創新者正利用先進的治療平台，促進基因療法候選藥物和基於微生物組的干涉措施的合作開發。大型企業與靈活敏捷的生物技術公司之間的合作，透過整合在製程開發和臨床營運方面的互補專長，加速了後期臨床試驗的進程。

為推動 IBD 的永續成長、改善患者預後以及加強關鍵相關人員。

產業領導企業應優先投資於針對疾病潛在機制的差異化治療方法，例如具有更高標靶特異性和更持久療效的新一代生物製劑。同時，將數位健康解決方案整合到臨床試驗通訊協定和上市後監測中，可以促進以患者為中心的參與，並產生真實世界數據（REW），從而支持醫保報銷談判。此外，與包括學術研究機構、患者權益組織和合約開發組織（CDO）在內的廣泛相關人員開展合作，將加速轉化研究並簡化與監管機構的溝通。

採用穩健的調查方法，結合多方面的資料收集、定性和定量分析以及嚴格的檢驗過程。

本研究採用多方面方法，結合廣泛的二手資料回顧和透過對行業高管、臨床醫生和支付方進行深度訪談而獲得的第一手資訊。二手研究涵蓋同行評審文章、監管申報文件、臨床試驗資料庫和行業白皮書，從而對治療機制、競爭格局和市場准入趨勢建立了紮實的基礎理解。第一手研究包括與全球意見領袖進行結構化討論，揭示了臨床應用促進因素和患者管理挑戰的細微觀點。

綜合關鍵研究成果和未來展望，為不斷發展的發炎性腸道疾病治療市場的相關人員提供全面結論。

本執行摘要整合了影響發炎性腸道疾病 (IBD) 治療市場的關鍵趨勢，涵蓋了從新型療法和先進治療方法到預期價格調整的策略意義等各個方面。細分市場分析揭示了產品在治療類型、給藥途徑、劑型和患者族群等方面實現差異化的關鍵途徑。區域洞察重點關注了不同的成長促進因素，包括美洲成熟的醫保報銷環境、歐洲、中東和非洲 (EMEA) 地區的監管協調工作以及亞太地區成長要素的激增。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 發炎性腸道疾病治療市場（依治療方法）

  • 先進治療方法
    • 基因治療
    • 微生物組調節劑
    • 幹細胞療法
  • 生物製藥
    • 整合素受體拮抗劑
    • 白細胞介素抑制劑
    • TNF抑制劑
  • 小分子藥物
    • 氨基水楊酸製劑
    • 皮質類固醇
    • 免疫抑制劑
  • 手術治療
    • 結腸造口術
    • 切除
    • 狹窄成形術

第9章 發炎性腸道疾病治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服
  • 直腸

第10章：以劑型分類的發炎性腸道疾病治療市場

  • 液體
    • 口服液體藥物
    • 懸浮液
  • 注射劑
  • 固態劑型
    • 咀嚼片
    • 緩釋片

第11章 發炎性腸道疾病治療市場：依應用領域分類

  • 克隆氏症
  • 病因不明的結腸炎
  • 潰瘍性大腸炎

第12章 發炎性腸道疾病治療市場：依最終使用者分類

  • 診所
  • 居家照護設施
  • 醫院

第13章 發炎性腸道疾病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 發炎性腸道疾病治療市場病患細分

  • 成人
  • 老年人
  • 兒童

第15章 發炎性腸道疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 發炎性腸道疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 發炎性腸道疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國發炎性腸道疾病治療市場

第19章 中國發炎性腸道疾病治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Abivax
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • Entera Bio Ltd.
  • FutureGen Biopharmaceutical（Beijing）Co., Ltd.
  • GlaxoSmithKline PLC
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Morphic Therapeutic, Inc.
  • Nestle SA
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharma Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • TScan Therapeutics, Inc.
  • UCB SA
  • Viatris Inc.
  • Zealand Pharma A/S
Product Code: MRR-563BF1FCFF1E

The Inflammatory Bowel Disease Treatment Market was valued at USD 20.95 billion in 2025 and is projected to grow to USD 21.95 billion in 2026, with a CAGR of 4.99%, reaching USD 29.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.95 billion
Estimated Year [2026] USD 21.95 billion
Forecast Year [2032] USD 29.47 billion
CAGR (%) 4.99%

A Comprehensive Introduction to Emerging Dynamics and Critical Drivers Shaping the Inflammatory Bowel Disease Treatment Ecosystem

Inflammatory bowel disease encompasses a complex spectrum of chronic gastrointestinal disorders characterized by relapsing inflammation, significant patient morbidity, and an urgent need for more effective therapies. In recent years, the convergence of advanced biologic agents, precision medicine approaches, and expanding real-world data has transformed our understanding of disease pathophysiology and treatment paradigms. As clinical trials increasingly embrace molecular subtyping and innovative endpoints, stakeholders from pharmaceutical developers to healthcare systems are realigning their strategies to capitalize on emerging opportunities.

Furthermore, dynamic shifts in patient demographics, regulatory frameworks, and reimbursement landscapes are elevating the demand for differentiated therapeutic solutions. Healthcare providers are seeking treatments that offer sustained remission with minimized safety concerns, while payers are scrutinizing value propositions to manage the economic burden of chronic immune-mediated diseases. As a result, industry participants are deploying multidisciplinary research and forging cross-sector collaborations to accelerate the development of pioneering modalities that aim to redefine standards of care in inflammatory bowel disease.

Transformational Shifts Redefining Research, Treatment Modalities, and Patient Outcomes in the Evolving Inflammatory Bowel Disease Landscape

The inflammatory bowel disease landscape has undergone fundamental transformations driven by breakthroughs in targeted immunology and regenerative medicine. Historically dominated by small molecule drugs and corticosteroids, the market has shifted toward precision-targeted biologics such as integrin receptor antagonists and interleukin inhibitors, which offer superior safety and efficacy profiles. Concurrently, advanced therapies-including gene therapy vectors, microbiome modulators, and stem cell transplantation-are entering late-stage development, promising durable remission through restoration of mucosal integrity and immune homeostasis.

Moreover, digital health innovations and remote monitoring tools are enabling real-time disease management and empowering patients to actively participate in therapy regimens. Advances in telemedicine platforms are streamlining follow-up care, reducing hospitalizations, and improving adherence. In parallel, evolving regulatory pathways now accommodate breakthrough designations and adaptive trial designs, expediting the translation of laboratory discoveries into clinical interventions. Together, these shifts are redefining competitive dynamics and creating fertile ground for next-generation therapies that target the root causes of inflammatory bowel disease.

Assessing the Projected Cumulative Impact of 2025 United States Tariffs on Therapeutic Innovation and Market Accessibility in IBD Care

Anticipated adjustments in United States tariff policies for 2025 carry far-reaching implications for the inflammatory bowel disease therapy supply chain and cost structures. Increased import duties on key raw materials and active pharmaceutical ingredients may compel manufacturers to reassess sourcing strategies or absorb additional expenses, potentially affecting pricing negotiations and reimbursement discussions. Consequently, decision makers must monitor policy developments closely and explore alternative materials procurement or localized production partnerships to mitigate cost escalations.

Furthermore, tariff-induced pressures could accelerate interest in domestic biomanufacturing capabilities, spurring investments in flexible facilities and contract development organizations to localize critical manufacturing processes. Such a shift would not only buffer companies against external trade fluctuations but also enhance supply chain resilience. At the same time, collaborations with regulatory bodies and industry coalitions will be essential to navigate potential compliance hurdles and secure timely approvals. By proactively addressing these tariff dynamics, stakeholders can safeguard market access and maintain momentum in bringing innovative IBD therapies to patients.

Deep Dive into Segmentation Insights Revealing Treatment Modalities, Administration Routes, Formulation Types, Applications, End-Users, and Patient Demographics

The inflammatory bowel disease treatment market is dissected across multiple dimensions to reveal critical opportunities and unmet needs. Based on treatment type, research efforts extend from foundational small molecule drugs such as aminosalicylates, corticosteroids, and immunosuppressants to cutting-edge biologic classes including tumor necrosis factor inhibitors, interleukin blockers, and integrin receptor antagonists. Advanced therapies further diversify the landscape through gene therapy constructs designed to reset immune regulation, microbiome modulators aiming to restore gut flora balance, and stem cell therapies focused on regenerating damaged intestinal tissue. Surgical interventions remain integral for refractory cases, with procedures ranging from ostomy creation to resections and strictureplasties tailored to complex anatomical challenges.

In addition, administration route segmentation highlights the strategic relevance of injectable formulations delivered intravenously or subcutaneously, complemented by patient-preferred oral and rectal therapies that foster adherence. Formulation type analysis underscores the distinction between liquid formulations, such as oral solutions and suspensions, versus solid dosage forms including chewable and extended release tablets, alongside specialized parenteral preparations. Treatment applications concentrate on Crohn's disease, indeterminate colitis, and ulcerative colitis, each presenting unique pathophysiology and therapeutic endpoints. Moreover, end-user settings span traditional hospital environments, specialized clinics, and increasingly vital home care scenarios that support self-administration. Distribution channels cut across hospital pharmacies, online platforms, and retail outlets to optimize patient access. Finally, patient type considerations differentiate adult, geriatric, and pediatric populations, ensuring that product development and care models address distinct safety, dosing, and compliance factors across life stages.

Regional Insights Unveiling Distinct Growth Drivers and Patient Access Dynamics across the Americas, EMEA, and Asia-Pacific in IBD Therapeutics

Regional dynamics shape the inflammatory bowel disease treatment landscape in distinct ways. In the Americas, robust healthcare infrastructure and established reimbursement frameworks facilitate rapid adoption of novel therapies. Patient advocacy groups and clinical networks further drive awareness, supporting early diagnosis and adherence to long-term treatment regimens. However, emerging challenges include payer scrutiny of high-cost biologics and the imperative to demonstrate real-world value through comprehensive patient registries.

In Europe, the Middle East, and Africa, a mosaic of regulatory environments influences market entry strategies. Harmonization efforts across the European Union streamline approval pathways, whereas variable reimbursement policies in the Middle East and Africa necessitate adaptive pricing models. Local manufacturing partnerships and public-private initiatives are increasingly critical to improve therapy availability and address regional disease burdens. Across Asia-Pacific, escalating IBD incidence, bolstered by lifestyle shifts and urbanization, is prompting governments to prioritize chronic disease management. Incentives for domestic biotech innovation and strategic licensing agreements are propelling new entrants into this high-growth arena, while generics and biosimilars play an essential role in expanding patient access.

Strategic Company Profiles and Competitive Positioning Highlighting Innovation Pathways and Market Leadership in Inflammatory Bowel Disease Treatment

Leading pharmaceutical and biotechnology companies are pursuing diverse strategies to secure their positions in the inflammatory bowel disease arena. Established players are enhancing their biologics portfolios with next-generation antibody constructs and biosimilar development programs. Meanwhile, emerging innovators are capitalizing on advanced therapy platforms, forging alliances to co-develop gene therapy candidates and microbiome-based interventions. Collaborative ventures between large-cap firms and nimble biotechs are accelerating late-stage trials, leveraging complementary expertise in process development and clinical operations.

Competitive positioning is also influenced by robust intellectual property protection and strategic patent litigation, as companies seek to extend exclusivity periods for high-value assets. In parallel, royalty monetization agreements and divestitures of non-core assets are optimizing balance sheets, enabling reinvestment in high-potential pipelines. As regulatory agencies exhibit greater flexibility through accelerated pathways and conditional approvals, organizations equipped with adaptive clinical trial designs and real-world evidence capabilities will gain a decisive advantage. Overall, the interplay of M&A activity, co-development partnerships, and innovation-driven collaboration is reshaping the competitive terrain.

Actionable Strategic Recommendations to Drive Sustainable Growth, Enhance Patient Outcomes, and Foster Collaboration among Key Stakeholders in IBD

Industry leaders should prioritize investment in differentiated modalities that address underlying disease mechanisms, such as next-generation biologics with enhanced targeting specificity and durable response profiles. In parallel, integrating digital health solutions into clinical trial protocols and post-market surveillance can foster patient-centric engagement and generate real-world evidence to support reimbursement negotiations. Furthermore, cultivating multi-stakeholder collaborations-including alliances with academic research centers, patient advocacy groups, and contract development organizations-will accelerate translational research and streamline regulatory interactions.

Moreover, supply chain resilience should be fortified by diversifying manufacturing footprints and exploring regional production partnerships to mitigate tariff impacts and logistical disruptions. Organizations are encouraged to adopt modular facility designs and flexible contract manufacturing strategies to adapt to evolving demand patterns. Lastly, a concerted focus on emerging markets-supported by localized value demonstration and tiered pricing frameworks-will unlock high-growth opportunities while advancing equitable access to transformative therapies.

Robust Research Methodology Combining Multi-Source Data Collection, Qualitative and Quantitative Analyses, and Rigorous Validation Processes

This research integrates a multi-source approach, combining extensive secondary data review with primary insights gathered through in-depth interviews with industry executives, clinicians, and payers. Secondary research encompassed peer-reviewed publications, regulatory filings, clinical trial databases, and industry white papers to establish a robust foundational understanding of therapeutic mechanisms, competitive landscapes, and market access dynamics. Primary engagements involved structured discussions with opinion leaders across geographies, uncovering nuanced perspectives on clinical adoption drivers and patient management challenges.

Quantitative analysis was conducted using proprietary data models that triangulate findings across independent datasets, ensuring rigorous validation of thematic conclusions. Qualitative thematic coding was applied to interview transcripts to identify recurring trends, unmet clinical needs, and strategic imperatives. Iterative validation workshops with domain experts further refined key insights and resolved information gaps. Together, these methodologies provide a comprehensive, reliable, and actionable framework for stakeholders navigating the inflammatory bowel disease treatment arena.

Comprehensive Conclusion Synthesizing Key Findings and Future Outlook for Stakeholders in the Evolving Inflammatory Bowel Disease Treatment Market

This executive summary has synthesized pivotal developments shaping the inflammatory bowel disease treatment market, from emerging therapeutic classes and advanced modalities to the strategic implications of anticipated tariff changes. Segmentation analysis has illuminated critical pathways for product differentiation across treatment types, administration routes, formulation formats, and patient demographics. Regional insights underscore the multiplicity of growth drivers-from mature reimbursement landscapes in the Americas to regulatory harmonization efforts in EMEA and surging demand trajectories in Asia-Pacific.

Competitive intelligence reveals that innovation convergence, strategic partnerships, and agile manufacturing approaches will determine market leadership moving forward. Actionable recommendations emphasize the importance of targeted investment in next-generation therapies, digital health integration, supply chain resilience, and market-specific access strategies. As stakeholders chart their strategies for 2025 and beyond, a proactive, evidence-based approach will be essential to unlocking value, enhancing patient outcomes, and sustaining long-term growth in this dynamic and high-stakes therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Inflammatory Bowel Disease Treatment Market, by Treatment Type

  • 8.1. Advanced Therapies
    • 8.1.1. Gene Therapy
    • 8.1.2. Microbiome Modulators
    • 8.1.3. Stem Cell Therapy
  • 8.2. Biologics
    • 8.2.1. Integrin Receptor Antagonists
    • 8.2.2. Interleukin Inhibitors
    • 8.2.3. TNF Inhibitors
  • 8.3. Small Molecule Drugs
    • 8.3.1. Aminosalicylates
    • 8.3.2. Corticosteroids
    • 8.3.3. Immunosuppressants
  • 8.4. Surgical Procedures
    • 8.4.1. Ostomy
    • 8.4.2. Resection
    • 8.4.3. Strictureplasty

9. Inflammatory Bowel Disease Treatment Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral
  • 9.3. Rectal

10. Inflammatory Bowel Disease Treatment Market, by Formulation Type

  • 10.1. Liquid Formulations
    • 10.1.1. Oral Solutions
    • 10.1.2. Suspensions
  • 10.2. Parenteral Preparations
  • 10.3. Solid Dosage Forms
    • 10.3.1. Chewable Tablets
    • 10.3.2. Extended Release Tablets

11. Inflammatory Bowel Disease Treatment Market, by Application

  • 11.1. Crohns Disease
  • 11.2. Indeterminate Colitis
  • 11.3. Ulcerative Colitis

12. Inflammatory Bowel Disease Treatment Market, by End-User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals

13. Inflammatory Bowel Disease Treatment Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Inflammatory Bowel Disease Treatment Market, by Patient Type

  • 14.1. Adult Population
  • 14.2. Geriatric Population
  • 14.3. Pediatric Population

15. Inflammatory Bowel Disease Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Inflammatory Bowel Disease Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Inflammatory Bowel Disease Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Inflammatory Bowel Disease Treatment Market

19. China Inflammatory Bowel Disease Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. AbbVie Inc.
  • 20.7. Abivax
  • 20.8. Amgen Inc.
  • 20.9. Bristol-Myers Squibb Company
  • 20.10. Cipla Limited
  • 20.11. Eli Lilly and Company
  • 20.12. Entera Bio Ltd.
  • 20.13. FutureGen Biopharmaceutical (Beijing) Co., Ltd.
  • 20.14. GlaxoSmithKline PLC
  • 20.15. Ironwood Pharmaceuticals, Inc.
  • 20.16. Johnson & Johnson Services, Inc.
  • 20.17. Merck & Co., Inc.
  • 20.18. Morphic Therapeutic, Inc.
  • 20.19. Nestle S.A.
  • 20.20. OPKO Health, Inc.
  • 20.21. Pfizer Inc.
  • 20.22. Sanofi SA
  • 20.23. Sun Pharma Limited
  • 20.24. Takeda Pharmaceutical Company Limited
  • 20.25. Teva Pharmaceutical Industries Ltd.
  • 20.26. TScan Therapeutics, Inc.
  • 20.27. UCB S.A.
  • 20.28. Viatris Inc.
  • 20.29. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 276. GC